Where is the direction for raw material pharmaceutical companies to turn to characteristic raw materials and preparations

Before the embarrassment of API companies, Xinhua Pharmaceutical, located in Zibo, Shandong Province, was most afraid of Encyclopedia Hendi, located in Jingmen, Hubei Province, which was also a domestic enterprise that produced ibuprofen, with the output of encyclopedia ranking first all year round, Xinhua ranking second, and the right to speak was always in the hands of the boss But slowly, Xinhua Pharmaceutical is not afraid Why? They had already transformed into preparations After listening to the story, it can be understood that people can't play but run away, or that the ideas become wider and wider After the unremitting transformation and upgrading, Shandong seven patent medicine enterprises began to sell preparations Such a story happened to Yichang dongyangguang Pharmaceutical Co., Ltd A few years ago, they found a Taiwanese boss who wanted to cooperate in API projects Unexpectedly, the opposite boss asked, "even the cephalosporin intermediates of niuqi dropped from $9000 per kilogram to $900 Do you still make APIs?" A sentence awakens dongyangren, and they also pay more attention to preparations "Compared with other industries, pharmaceutical industry has the advantages of high added value, anti cycle and less market impact However, being satisfied with bulk API production turns these advantages into disadvantages " Wang Xuehai, chairman of humanwell Pharmaceutical Group Co., Ltd., pointed out In his opinion, if a province's pharmaceutical industry relies on the sale of APIs, it must attract enough attention and consideration Characteristic APIs and preparations are the direction of "single product structure, low added value This is the general embarrassment faced by API enterprises in Hubei Province! " Li Bing, President of the provincial pharmaceutical industry association, pointed out No enterprise is willing to wait and die, what is blocking the pace of transformation? The role of generic drugs in preparations is equal to that of bulk APIs in APIs If the API is only transformed to generic drugs, it is of little significance If it is to be transformed, it is necessary to develop new drugs However, for many enterprises, new drugs are peaches that can't be picked The average cycle of developing a new drug from laboratory to clinic is about 12 years, and the R & D cost is hundreds of millions, which is a huge challenge to the small and medium-sized pharmaceutical industry It's very important to choose the right way to go Fortunately, there are not many pioneers Yichang East Sunshine Pharmaceutical Co., Ltd cooperates with Pfizer, a global pharmaceutical giant, to produce azithromycin, a downstream product of erythromycin; derivatives such as clarithromycin and roxithromycin independently researched and developed have also been put into production, and the profits are expected to increase significantly In addition, the company's self-developed gene recombination of insulin strains will become a product with a single product sales revenue of more than 10 billion yuan At present, the derivative of ibuprofen API in the province has been put into production in Encyclopedia Hendy, with the output value of 100 tons of ibuprofen equivalent to 4000 tons of ibuprofen; the derivative of riboflavin, riboflavin sodium phosphate, has also been put into production, with the profit increased by 40% "APIs improve profitability by making standards, while preparations are making systems." Yuanda pharmaceutical said that the development of preparations is the long-term consideration of the enterprise At present, there are nearly 40 projects under research "According to their own reality, enterprises with good foundation and strong R & D ability should accelerate the pace of R & D of new drugs and transform into preparations In addition, the transformation from bulk API to characteristic API is also a desirable direction " Li Bing said that when consolidating their original advantages, API manufacturers should gradually transform to pharmaceutical production, give full play to their dual advantages, occupy the pharmaceutical terminal market and change the situation of being controlled by others The core of non innovation is research and development At present, the largest R & D investment in the province is humanwell, accounting for about 10% of the sales revenue The R & D cost of about 500 million yuan each year has achieved today's humanwell The R & D investment of dongyangguang pharmaceutical industry accounts for 8%, Yuanda for 5%, and Jianmin for 3.5% The average R & D investment of pharmaceutical enterprises in the whole province is 2%, and there are not a few enterprises whose investment is less than 1% Since 2006, the province's pharmaceutical industry has obtained 490 new drug approvals At the same time, the pharmaceutical industry in Shandong Province has obtained 800 new drug approval certificates, including 17 first-class new drugs, and the number of new drugs on the market ranks first in China The gap is clear Among the top 50 pharmaceutical companies in the world, the annual R & D investment accounts for an average of 15% to 20% of sales, with a maximum of more than 30% and a minimum of nearly 10% The lack of innovation ability of the pharmaceutical industry in the whole province is not only due to the lack of enterprise innovation consciousness, but also limited by the lack of enterprise strength As early as 2000, Encyclopedia Hendy has tried the research and development in the field of gene medicine, and established a research and development institution in cooperation with colleges and universities in Wuhan "More than 20 million yuan has been invested successively, but it turns out that there is no bubble," said Zhang Xiaojun, general manager of Encyclopedia Hendy pharmaceutical, who had to give up the project Since then, with the fluctuation of business operation, R & D investment has dropped again and again Similar experiences have been encountered by many small and medium-sized pharmaceutical enterprises As for the R & D bottleneck encountered by small and medium-sized enterprises, Li Bing suggested that we should take the road of combining production, learning and research, as long as we have a good eye on new product projects, make use of the strength of universities and research institutes to carry out scientific research and share results, or directly purchase new results from universities and research institutes for industrialization In view of the characteristics of the pharmaceutical industry, he called on the government to increase the support for the research and development of pharmaceutical enterprises and encourage independent innovation of pharmaceutical enterprises.